Featured Research

from universities, journals, and other organizations

Second round of gefitinib may be promising lung cancer therapy

Date:
January 12, 2010
Source:
American Association for Cancer Research
Summary:
Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.

Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.

"The key may be in tumor heterogeneity," said In-Jae Oh, M.D., Ph.D., assistant professor in Chonnam National University Hwasun Hospital in the Republic of Korea. "That is, within a tumor, some cells are independent of epidermal growth factor receptor and those will fail to respond, but we can continue to target the other cells that have become addicted to epidermal growth factor receptor."

For the current study, presented at the AACR-IASLC Joint Conference on Molecular Origins in Lung Cancer, which was held here from Jan. 11-14, 2010, Oh and colleagues evaluated 15 patients who were retreated with gefitinib after more than one cycle of chemotherapy for advanced or metastatic non-small cell lung cancer.

Among the six patients who had showed partial response with initial gefitinib treatment, two patients showed an additional partial response and three patients continued to show stable disease.

Among the nine patients who showed stable disease with the initial gefitinib treatment, two patients showed partial response and three patients showed stable disease. The overall disease control rate was 66.7 percent.

"After failure with gefitinib and subsequent chemotherapy, we can try gefitinib again especially for the patients who had previously responded to gefitinib. This strategy will keep some patients from the toxicities of chemotherapy and help maintain the quality of life for several months," said Oh.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Second round of gefitinib may be promising lung cancer therapy." ScienceDaily. ScienceDaily, 12 January 2010. <www.sciencedaily.com/releases/2010/01/100112165115.htm>.
American Association for Cancer Research. (2010, January 12). Second round of gefitinib may be promising lung cancer therapy. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2010/01/100112165115.htm
American Association for Cancer Research. "Second round of gefitinib may be promising lung cancer therapy." ScienceDaily. www.sciencedaily.com/releases/2010/01/100112165115.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins